GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B1352 BetaxololSummary: βadrenergic receptor blocker
- B2230 Trazodone HClSummary: 5-HT receptor antagonist
- B2234 Clomipramine HClSummary: SERT/NET dopamine transporter (DAT) blocker
- B1365 Terazosin HClSummary: Selective α1-adrenoceptor antagonist
- B1338 Maprotiline HClSummary: Selective noradrenalin re-uptake inhibitor
- B2242 Urapidil HClSummary: α1-adrenoceptor antagonist and 5-HT1A receptor agonist
- B2264 Dapoxetine HClSummary: Selective serotonin reuptake inhibitor
- B2248 KetanserinTarget: 5-HT2 ReceptorsSummary: specific 5-HT2A serotonin receptor antagonist
- B1354 Bisoprolol fumarateSummary: Selective α-adrenergic blocker
- B1362 NaftopidilSummary: α1-adrenergic receptor antagonist